Triumph Capital Management Grows Stock Position in Organon & Co. $OGN

Key Points

• Triumph Capital Management increased its stake in Organon & Co. by 109.1% in Q2, now owning 90,342 shares valued at approximately $875,000.
• BNP Paribas upgraded Organon & Co. to a "strong-buy" rating, contributing to a consensus rating of "Moderate Buy" with a target price of $17.33.
• The company reported earnings of $1.00 EPS for the last quarter, exceeding estimates, while its revenue totaled $1.59 billion, slightly above forecasts.

Triumph Capital Management lifted its stake in Organon & Co. (NYSE:OGN - Free Report) by 109.1% during the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm owned 90,342 shares of the company's stock after buying an additional 47,127 shares during the period. Triumph Capital Management's holdings in Organon & Co. were worth $875,000 as of its most recent SEC filing.

Several other large investors have also recently modified their holdings of the stock. SBI Securities Co. Ltd. increased its holdings in Organon & Co. by 17.6% during the 1st quarter. SBI Securities Co. Ltd. now owns 7,653 shares of the company's stock valued at $114,000 after purchasing an additional 1,145 shares during the period. Rafferty Asset Management LLC increased its holdings in Organon & Co. by 5.6% during the 4th quarter. Rafferty Asset Management LLC now owns 22,627 shares of the company's stock valued at $338,000 after purchasing an additional 1,194 shares during the period. Handelsbanken Fonder AB increased its holdings in Organon & Co. by 1.5% during the 1st quarter. Handelsbanken Fonder AB now owns 81,565 shares of the company's stock valued at $1,215,000 after purchasing an additional 1,200 shares during the period. Xponance Inc. increased its holdings in Organon & Co. by 15.2% during the 1st quarter. Xponance Inc. now owns 13,828 shares of the company's stock valued at $206,000 after purchasing an additional 1,823 shares during the period. Finally, Brown Advisory Inc. increased its holdings in Organon & Co. by 6.5% during the 1st quarter. Brown Advisory Inc. now owns 30,174 shares of the company's stock valued at $449,000 after purchasing an additional 1,835 shares during the period. Hedge funds and other institutional investors own 77.43% of the company's stock.

Analyst Ratings Changes

Separately, BNP Paribas upgraded Organon & Co. to a "strong-buy" rating in a report on Thursday, May 22nd. One investment analyst has rated the stock with a Strong Buy rating, two have given a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, Organon & Co. currently has a consensus rating of "Moderate Buy" and a consensus target price of $17.33.

Organon & Co. Stock Performance

OGN stock opened at $10.39 on Tuesday. The stock has a market capitalization of $2.70 billion, a PE ratio of 3.86, a price-to-earnings-growth ratio of 0.97 and a beta of 0.60. Organon & Co. has a 12-month low of $8.01 and a 12-month high of $21.06. The company has a current ratio of 1.65, a quick ratio of 1.13 and a debt-to-equity ratio of 11.98. The stock's 50 day simple moving average is $9.65 and its 200 day simple moving average is $10.79.

Organon & Co. (NYSE:OGN - Get Free Report) last released its quarterly earnings data on Tuesday, August 5th. The company reported $1.00 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.94 by $0.06. The business had revenue of $1.59 billion for the quarter, compared to analysts' expectations of $1.55 billion. Organon & Co. had a return on equity of 163.88% and a net margin of 11.15%.The firm's quarterly revenue was down .8% on a year-over-year basis. During the same period in the prior year, the firm posted $1.12 EPS. Organon & Co. has set its FY 2025 guidance at EPS. As a group, research analysts forecast that Organon & Co. will post 3.68 earnings per share for the current fiscal year.

Organon & Co. Announces Dividend

The business also recently announced a quarterly dividend, which was paid on Thursday, September 11th. Shareholders of record on Friday, August 15th were paid a dividend of $0.02 per share. The ex-dividend date was Friday, August 15th. This represents a $0.08 dividend on an annualized basis and a yield of 0.8%. Organon & Co.'s payout ratio is currently 2.97%.

Organon & Co. Company Profile

Organon & Co is a science based global pharmaceutical company, which develops and delivers innovative health solutions through a portfolio of prescription therapies within women's health, biosimilars and established brands. The company was founded on March 11, 2020, and is headquartered in Jersey City, NJ.

Want to see what other hedge funds are holding OGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Organon & Co. (NYSE:OGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.